Director

Fariborz Kamal, Ph.D.

Former President and Chief Operating Officer; Chief Technical Advisor·4D Molecular Therapeutics, Inc.

About

Joined as Chief Technical Officer in October 2018 and added Chief Operating Officer in February 2020; promoted to President and COO in September 2022. Resigned as President and COO effective December 31, 2025 and transitioned to a part-time Chief Technical Advisor role. Former SVP of Quality and Regulatory CMC at AveXis.

Since 2018
Tenure 8 yrs

Also at 4D Molecular Therapeutics, Inc.

DM David Kirn, M.D. Co-Founder, President, Chief Executive Officer and Director JP John F. Milligan, Ph.D. Director and Executive Chairman JM Jacob Chacko, M.D., MBA Director SM Susannah Gray, MBA Director CP Charles P. Theuer, M.D., Ph.D. Director NM Nancy Miller-Rich Director

Roles

Organization Role Dates Details
4D Molecular Therapeutics, Inc. Former President and Chief Operating Officer; Chief Technical Advisor 2018–present Current role

Related

Company 4D Molecular Therapeutics, Inc. Company hub Person David Kirn, M.D. Co-Founder, President, Chief Executive Officer and Director Person John F. Milligan, Ph.D. Director and Executive Chairman Person Jacob Chacko, M.D., MBA Director Person Susannah Gray, MBA Director Person Charles P. Theuer, M.D., Ph.D. Director Person Nancy Miller-Rich Director Person Shawn Cline Tomasello, MBA Director Person Glenn Sblendorio Director Person Kristian Humer Chief Financial Officer Person Christopher Simms Chief Commercial and Business Officer Person Scott Bizily, J.D., Ph.D. Chief Legal Officer and Corporate Secretary Person Ashoo Gupta Vice President, Finance and Controller
Source: 4D Molecular Therapeutics, Inc. proxy statement (SEC Schedule 14A)

Where the filing does not disclose a value, this page states "Not disclosed" rather than estimating. Smaller filers are exempt from disclosing metric targets and achievement, and larger filers may omit forward targets for competitive reasons.

See how VectorShift works for your firm

Request Demo